Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07677475 | MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 65 | Dongguan People's HospitalOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03085147 | A Dye for the Detection of Cancer of the Tongue and Mouth | active not recruiting | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT07713901 | Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | enrolling by invitation | — | 93,600,000 | Novo Nordisk A/SINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07717307 | Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread(ExtentN1) | recruiting | N/A | 80 | Kolhapur Cancer Centre - Cancer Centers of AmericaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07726199 | Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread(ExtentN0) | recruiting | N/A | 267 | Kolhapur Cancer Centre - Cancer Centers of AmericaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745803 | Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma | not yet recruiting | — | 4,000 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | terminated | N/A | 152 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03803774 | Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06819228 | Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer | recruiting | Phase 1 | 70 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741110 | Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy | completed | — | 141 | Hellenic Cooperative Oncology GroupOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Early Phase 1 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07741643 | Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT02567422 | Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04747054 | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers(PembroMetaRT) | recruiting | Phase 3 | 102 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05669664 | Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06367257 | App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy | recruiting | N/A | 148 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06947668 | Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel(DoIT_Neck) | recruiting | — | 250 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07121595 | Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial | recruiting | Phase 2 | 50 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) | terminated | Phase 2 | 80 | Elevar TherapeuticsINDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04290546 | CIML NK Cell in Head & Neck Cancer | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07172256 | CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01468896 | Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT06580054 | Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06854510 | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. | active not recruiting | Phase 2 / Phase 3 | 196 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | not yet recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03612531 | Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors(MANTLE) | active not recruiting | N/A | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma(MRG003-SACC) | recruiting | Phase 2 | 40 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04754321 | Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer | recruiting | Phase 1 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03247712 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 22 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06437522 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 46 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07528183 | Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04877613 | GFRα4 CAR T Cells in MTC Patients | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT05419089 | The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | recruiting | Phase 2 | 83 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05973656 | Role of Acetaldehyde in the Development of Oral Cancer | recruiting | N/A | 170 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06798922 | Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers(OPTIFLAP) | recruiting | Phase 3 | 348 | Centre Francois BaclesseOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07168785 | [18F]-AraG PET Imaging in LA HNSCC | not yet recruiting | Early Phase 1 | 5 | Indiana UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials